Table 2 PMBCL first line therapy
Overall cohort | Rituximab treatment | No Rituximab treatment | |
|---|---|---|---|
Patient number, N (%) | 80 (100) | 45 (56) | 35 (44) |
Induction chemotherapy regimens, N (%)a | |||
6xR-CHOP | 21 (27) | 21 (47) | / |
6xR-CHOEP | 23 (29) | 23 (51) | / |
3xR-CHOP/3xR-CHOEP | 1 (1) | 1 (2) | / |
CHOP, median 5 (range 1–8) | 13 (16) | / | 13 (38) |
CHOEP, median 6 (range 3–7) | 13 (16) | / | 13 (38) |
Mega-CHOEP, median 4 (range 1–5) | 8 (10) | / | 8 (24) |
Response to induction chemotherapy, N (%) | |||
CR | 17 (21) | 6 (13) | 13 (37) |
PR | 60 (75) | 39 (87) | 19 (54) |
PD | 3 (4) | 0 (0) | 3 (9) |
Consolidation HD and ABSCT, N (%) upon: | |||
Mega-CHOEP | 6 (8) | 0 (0) | 6 (17) |
HD-BEAM | 18 (23) | 7 (16) | 11 (31) |
Overall | 24 (30) | 7 (16) | 17 (49) |
Radiation therapy, N (%) | 70 (88) | 41 (91) | 29 (83) |
Overall response after fist line therapy, N (%)b | |||
CR | 32 (41) | 15 (34) | 17 (49) |
PR | 43 (54) | 28 (64) | 15 (43) |
PD | 4 (5) | 1 (2) | 3 (9) |
Rituximab maintenance therapy, N (%) | 25 (31) | 24 (53) | 1 (3) |